https://www.m-ventures.com/ 2024-03-12T07:54:39+00:00 1.00 https://www.m-ventures.com/portfolio 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/team 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/career 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news?year=2024 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/contact 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news/beeoled-welcomes-new-advisory-board-member-and-chairman-gerd-gunther 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news/asceneuron-expands-scientific-advisory-board-with-world-leading-experts-in-neurodegenerative-diseases 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news/plexium-announces-appointment-of-michael-martin-ph-d-as-president-and-ceo 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news/disco-pharmaceuticals-launches-as-the-surfaceome-company-with-eur-20-million-in-seed-financing 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news/m-ventures-portfolio-company-calypso-a-merck-spin-out-enters-into-agreement-to-be-acquired-by-novartis 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news/polaris-electro-optics-inc-raises-seed-round-to-revolutionize-optical-interconnects 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/news 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/impressum 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/terms 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/privacy 2024-03-12T07:54:39+00:00 0.80 https://www.m-ventures.com/portfolio/actithera 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/ambrx 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/anavo 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/artios 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/asceneuron 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/calypso-biotech 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/disco 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/epitherapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/f-star-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/forendo-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/forx-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/future-fertility 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/galecto-biotech 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/immunebridge 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/immunitas 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/immunorizon 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/inthera 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/iomx-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/ionctura 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/multitude 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/nouscom 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/nucleome 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/obseva 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/outrun-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/padlock-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/plexium 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/prexton-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/progyny 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/rewind 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/ribometrix 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/riffyn 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/sentaur-biosciences 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/storm-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/synaffix-bv 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/theolytics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/tocopherx 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/translate-bio 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/vaximm 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/x-ilio-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/astraveus 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/cellfe 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/dna-script 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/genopore 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/iktos 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/lightcast 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/nanosyrinx 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/pictor-labs 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/scipio-bioscience 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/beeoled 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/celestial-ai 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/electroninks 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/ferroelectric-memory-gmbh 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/ikas 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/lumiode 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/memryx 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/metalenz 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/neologic 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/pacific-lights-hologram 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/peratech 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/polaris-electro-optics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/pxe 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/quintessent 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/seeqc 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/synsense 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/tignis 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/unisers 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/akili 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/altoida 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/biolinq 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/concerto-biosciences 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/formo 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/medisafe 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/micropsi-industries 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/mosa-meat 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/neurable 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/sonde-health 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/portfolio/wiliot 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/hakan-goker 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/owen-lozman 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/javier-rodriguez 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/bauke-anninga 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/christian-patze 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/christian-uhrich 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/daniel-franke 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/noga-yerushalmi 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/sebastian-schoefer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/therese-liechtenstein 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/ilja-aizenberg 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/nadiya-ishnazarova 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/oliver-hardick 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/eyal-ben-ami 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/sarah-luppino 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/tobias-egle 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/robert-even 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/charlotte-kremers 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/bjorn-kuhl 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/isabell-hammann 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/leonie-willemse 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/nino-machavariani 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/m-ventures-co-leads-a-67-5-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-appoints-marguerite-hutchinson-j-d-as-chief-business-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/https-www-femtechworld-co-uk-news-cegyr-leads-as-first-fertility-clinic-globally-to-use-future-fertilitys-ai-powered-egg-assessm 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/https-www-prnewswire-com-news-releases-cellfe-secures-22-million-in-series-a-financing-to-advance-microfluidics-based-cellular-e 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/anavo-therapeutics-strengthens-management-team 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/astraveus-raises-16-5-million-series-seed-round 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/metalenz-launches-its-metasurface-optics-on-the-open-market-in-partnership-with-umc 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-raises-38-5-million-in-series-b-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/altoida-appoints-marc-jones-as-chief-executive-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/lonza-to-acquire-synaffix-and-strengthen-antibody-drug-conjugates-offering 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/anavo-therapeutics-extends-seed-round-to-eur-28-million-to-advance-pipeline-of-novel-phosphatase-modulators-toward-the-clinic 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/immunebridge-raises-12m-from-m-ventures-and-insight-partners-to-advance-novel-natural-killer-nk-cell-based-immunotherapies 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-to-present-pharmacology-results-demonstrating-obe022-exerts-a-synergistic-effect-in-combination-with-standard-of-care-in- 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/seeqc-unveils-first-fully-digital-chips-for-full-stack-quantum-computers 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-announces-expansion-of-adc-collaboration-with-macrogenics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/iktos-raises-15-5m-series-a-round 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/iomx-therapeutics-appoints-dr-christine-rothe-as-new-cdo 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/unisers-raises-14m-seed-round 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/explore-applications-of-quantum-computing-in-chemical-reactions-for-industrial-use 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/effortlessly-develop-and-deploy-ai-on-memryx-edge-ai-processors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/chong-kun-dang-pharm-licenses-synaffix-adc-technology 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/metalenz-wins-2023-prism-award 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/purple-biotech-acquires-immunorizon-and-its-portfolio-of-tri-specific-antibodies 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/rewind-therapeutics-adds-sunstone-life-science-ventures-a-s-as-new-investor 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-presents-stc-15-preclinical-data 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-expands-r-d-leadership-team 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-provides-development-update-on-pi3k-inhibitor 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-enters-2-billion-license-agreement-with-amgen 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/first-patient-dosed-in-phase-1-2a-study-of-imt-009 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/metalenz-to-participate-in-emd-electronics-tech-talks 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/hummingbird-bioscience-and-synaffix-enter-150m-license-agreement 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/pictorlabs-launches-with-more-than-18-8-million-to-advance-transformative-virtual-staining 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-awarded-eur17-5-million-funding-from-the-eic-accelerator-for-clinical-development-of-novel-pancreatic-cancer-therapy 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/calypso-biotech-announces-first-patient-with-eosinophilic-esophagitis-dosed-in-antiinterleukin-15-il-15-monoclonal-antibody-caly 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-announces-closing-of-usd-30m-series-b-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/another-award-for-synaffix-business-development-team-of-year-at-the-scrip-awards 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-initiates-phase-ib-pancreatic-cancer-trial-of-next-generation-autotaxin-inhibitor-ioa-289 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/electroninks-partners-with-citrine-informatics-to-develop-enhanced-silver-ink-using-ai-assisted-r-d 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-named-biotech-company-of-the-year-at-the-lsx-european-lifestars-awards 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-announces-pipeline-and-business-updates-and-third-quarter-2022-financial-results 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/concerto-biosciences-raises-23-million-in-series-a 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/m-ventures-leads-oversubscribed-37-5-million-series-a-financing-of-nucleome-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-licenses-clicr-chemistry-from-cristal-therapeutics-to-fortify-best-in-class-adc-technology-offering 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/theolytics-presents-caf-targeting-therapy-for-stromal-rich-tumours-and-strengthens-leadership-team 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/future-fertility-s-ai-powered-oocyte-assessment-tools-receive-ce-mark 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/fierce-biotech-names-storm-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2022 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-appoints-new-ceo 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-is-now-listed-on-nasdaq 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-announces-encouraging-preliminary-phase-1-dose-escalation-data-for-xtx101-a-tumor-selective-anti-ctla-4-and-r 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/plexium-appoints-brian-wong-to-its-board-of-directors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/m-ventures-invests-in-tignis-for-sustainability-in-semiconductor-mfg-in-series-a 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/metalenz-and-stmicroelectronics-deliver-world-s-first-optical-metasurface-technology-for-consumer-electronics-devices 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/scipio-bioscience-selected-for-2-5m-european-innovation-council-grant 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/altoida-appoints-neuroscience-pioneer-dr-antontella-santuccione-chadha-as-chief-medical-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/theolytics-1m-project-with-innovateuk-to-develop-a-novel-therapy-for-multiple-myeloma-patients 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-awarded-second-grant-from-the-michael-j-fox-foundation 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/plexium-appoints-stephen-mullennix-as-chief-financial-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/future-fertility-announces-new-ceo 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/abbvie-and-plexium-enter-into-multi-target-strategic-collaboration-to-develop-and-commercialize-targeted-protein-degradation-the 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/electroninks-announces-production-scale-availability-of-full-suite-of-metal-complex-conductive-ink-solutions 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synsense-steps-into-the-field-of-smart-cockpits-by-initiating-a-technological-exploration-with-bmw 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-launches-early-access-program-for-latest-advancements-to-the-syntax-platform-and-enzymatic-dna-synthesis-technology 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-data-at-aacr-demonstrates-unique-mechanism-of-action-for-clinical-stage-autotaxin-inhibitor-ioa-289 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-partners-with-asia-pacific-distributors-as-part-of-global-expansion-to-meet-demand-for-same-day-enzymatic-dna-synthes 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-publishes-preclinical-efficacy-data-on-asn90 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/cybernews-interview-with-metalenz-co-founder-and-ceo-rob-devlin 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/altoida-upsizes-its-series-a-round-to-20-3m-to-advance-its-first-in-class-ai-powered-neurocognitive-assessment-platform 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dr-marie-mcavoy-joins-nanosyrinx-as-chief-scientific-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-to-present-preclinical-data-on-its-clinical-stage-autotaxin-inhibitor-ioa-289-at-aacr 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-named-to-fast-company-s-annual-list-of-the-world-s-50-most-innovative-companies-for-2022 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/nec-oncoimmunity-acquires-vaximm-s-neoantigen-vaccine-development-assets 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-named-to-fast-company-s-annual-list-of-the-world-s-most-innovative-companies-for-2022 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/plexium-announces-102m-financing-to-advance-pipeline-of-targeted-protein-degradation-therapies-and-technology-platform 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-joins-wellcome-leap-r3-program-to-advance-rna-products-and-therapies 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/celestial-ai-raises-56-million-series-a-to-disrupt-the-artificial-intelligence-chipset-industry-with-novel-photonic-electronic-t 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/amgen-and-plexium-announce-multi-year-drug-discovery-collaboration-to-identify-novel-targeted-protein-degradation-therapies 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-to-become-publicly-traded-through-combination-with-social-capital-suvretta-holdings-corp-i 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/scipio-bioscience-launches-commercialization-in-europe-of-asteria-its-rna-sequencing-kit 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/metalenz-launches-gemini-to-make-3d-sensing-easier-with-selectable-illuminator-optics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-2-clinical-trial-of-xtx202-for-the-treatment-of-patients-wi 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/future-fertility-raises-series-a-to-progress-first-in-class-ai-enabled-fertility-solutions-to-improve-ivf-outcomes 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/anavo-therapeutics-announces-the-appointment-of-charles-mcdermott-as-chairman-of-the-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ai-chip-innovator-memryx-hires-veteran-semiconductor-leader-keith-kressin-as-ceo 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/merck-kgaa-darmstadt-germany-expands-corporate-venture-fund-m-ventures-with-a-new-investment-of-600-million 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-obtains-ce-mark-for-syntax-dna-printing-platform 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/plexium-appoints-percival-barretto-ko-as-president-and-chief-executive-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-raises-165m-in-oversubscribed-series-c-financing-to-accelerate-commercialization-of-enzymatic-dna-printing-platform 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-announces-closing-of-initial-public-offering 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-xtx202-for-the-treatment-of-solid-tumors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/altoida-launches-5-year-multi-center-alzheimer-s-study-with-eisai-and-ionian-university 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/iomx-therapeutics-raises-eur-65-million-in-series-b-round 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/third-adc-with-synaffix-s-technology-enters-clinical-development 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-2-clinical-trial-of-xtx101-for-the-treatment-of-patients-wi 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/altoida-unveils-new-brand-identity-with-reimagined-logo-and-website 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/altoida-awarded-fda-breakthrough-designation-for-development-of-world-s-first-precision-neurology-device-for-prediction-of-alzhe 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/nanosyrinx-announces-oversubscribed-6-2m-seed-funding-round-to-develop-its-novel-biologic-delivery-platform 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/theolytics-expands-series-a-financing-and-welcomes-m-ventures-as-a-new-investor 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/anavo-therapeutics-strengthens-scientific-advisory-board-with-industry-leading-drug-discovery-experts-in-oncology 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-announces-clinical-trial-collaboration-with-merck-on-anti-ctla-4-monoclonal-antibody-program 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/soteria-biotherapeutics-launches-with-42-million-series-a-financing-led-by-roche-venture-fund-and-5am-ventures 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/anavo-therapeutics-launches-with-eur-20-million-seed-financing-to-create-industry-leading-pipeline-of-allosteric-phosphatase-mod 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/forx-therapeutics-ag-appoints-tarig-bashir-as-chief-executive-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-expands-scientific-advisory-board-with-the-appointment-of-professor-tsutomu-suzuki 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/forendo-pharma-successfully-completes-phase-1-studies-of-for-6219-in-endometriosis-aiming-to-advance-program-into-phase-2-clinic 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-raises-95-million-in-series-c-financing-to-advance-potent-tumor-selective-immuno-oncology-pipeline 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-announces-the-start-of-first-clinical-study-with-the-dosing-of-its-atr-inhibitor-art0380-to-patients 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/plexium-announces-35m-financing-to-advance-pipeline-of-novel-protein-degraders 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/merck-kgaa-darmstadt-germany-and-artios-pharma-announce-a-global-strategic-collaboration-on-novel-dna-damage-response-targets-in 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ferroelectric-memory-gmbh-fmc-raises-20-million-to-accelerate-next-generation-memory-for-ai-iot-edge-computing-and-data-center-a 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/calypso-biotech-announces-successful-dosing-of-first-phase-1-cohort-with-anti-interleukin-15-il-15-monoclonal-antibody-caly-002- 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/soteria-biotherapeutics-announces-scientific-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-presents-promising-preclinical-tumor-selective-efficacy-and-safety-data-for-xtx201-il-2-and-xtx101-anti-ctla- 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/galecto-announces-pricing-of-initial-public-offering 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-selects-first-in-class-clinical-candidate-targeting-mettl3 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synthetic-biology-start-up-nanosyrinx-secures-capital-to-develop-its-fully-customisable-platform-for-intra-cellular-engineering 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/galecto-raises-64-million-to-accelerate-development-of-clinical-pipeline 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/mosa-meat-raises-series-b-funding-to-prepare-for-large-scale-cultured-meat-production 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/rapid-prototyping-and-validation-of-sars-cov-2-clinical-diagnostic-workflows 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/sonde-health-purchases-neurolex-labs-voice-platform-and-500k-biometric-samples 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/dna-script-expands-series-b-to-89m 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-announces-third-deal-expansion-by-adc-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-appoints-paul-j-clancy-to-its-board-of-directors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/sonde-health-launches-new-voice-enabled-health-screening-tool-to-help-employers-return-to-work-during-the-global-pandemic 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/micropsi-industries-secures-two-new-specialized-investors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-announces-fda-clearance-of-endeavorrx-for-children-with-adhd-the-first-prescription-treatment-delivered-through-a-video-ga 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-appoints-industry-veteran-dr-joanna-horobin-as-chair 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/computers-modelled-on-the-human-brain 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/galecto-appoints-new-chair-and-strengthens-board-of-directors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/xilio-therapeutics-appoints-martin-h-huber-m-d-as-chief-medical-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-announces-endeavortm-digital-attention-treatment-is-now-available-for-children-with-attention-deficit-hyperactivity-disord 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/forx-therapeutics-ag-raises-eur-10-million-seed-round 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/seeqc-gains-over-11-million-in-funding-to-introduce-fully-digital-quantum-computing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/scipio-bioscience-raises-6-0-m-series-a-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-strengthens-clinical-development-team-with-senior-appointments 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-expands-its-clinical-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/neurable-raises-6-million-to-develop-brain-sensing-consumer-devices-beginning-with-headphones 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/berlin-based-startup-legendairy-foods-has-raised-4m-to-develop-cheese-and-other-dairy-products-that-have-the-same-composition-as 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/forendo-pharma-signs-important-license-and-collaboration-deal-with-leading-pharma-company 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/immunitas-therapeutics-launches-with-39-million-to-advance-lead-programs-to-human-efficacy-studies-based-on-a-unique-immunology- 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/nec-and-vaximm-announce-collaboration-to-advance-personalized-neoantigen-cancer-vaccines 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/plexium-launches-with-28-million-in-series-a-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/iomx-therapeutics-announces-discovery-of-novel-druggable-immune-checkpoint-targets 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-appoints-tania-dimitrova-as-chief-business-officer-and-expands-presence-in-the-united-states 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/riffyn-appoints-former-cisco-and-hp-executive-barbara-adey-to-board-of-directors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/sunstone-life-science-ventures-joins-forendo-pharma-investor-syndicate 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/first-programmable-memristor-computer-aims-to-bring-ai-processing-down-from-the-cloud 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/basf-is-collaborating-with-riffyn-on-white-biotechnology-r-d 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/john-conway-former-head-of-data-sciences-and-ai-at-astrazeneca-joins-riffyn-as-chief-commercial-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/larry-peck-former-vp-at-autodesk-joins-riffyn-as-vice-president-of-engineering 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/riffyn-enters-multi-year-contract-with-novozymes-for-r-d-data-analytics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/altoida-raises-6-3m-series-a-to-predict-alzheimer-s-disease-risk-using-artificial-intelligence-machine-learning-and-augmented-re 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/riffyn-raises-a-15m-series-b-to-accelerate-its-growth-in-life-sciences-r-d 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ge-healthcare-and-indi-molecular-to-collaborate-on-diagnostic-tool-for-clinical-management-of-immunotherapy-patients 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/sonde-completes-16-million-series-a-financing-round-to-advance-vocal-biomarker-technology 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-announces-appointment-of-dr-ian-smith-as-chief-medical-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-selected-for-an-oral-presentation-at-2019-aacr-annual-meetin 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-selected-for-an-oral-presentation-at-2019-aacr-annual-meeting 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-announces-appointment-of-professor-rajesh-chopra-as-non-executive-director 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/m-a-of-the-year-prexton-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-appoints-peter-van-vlasselaer-as-chairman 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/adc-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-of-adct-601-in-advanced-solid-tumors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-appoints-dr-thomas-c-wessel-as-chief-medical-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-initiates-neuroimaging-trial-for-tau-modifier-asn120290 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ribometrix-announces-30-million-series-a-funding-to-advance-pipeline-of-rna-targeting-small-molecule-therapies 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/galecto-biotech-raises-79-million-in-series-c-financing-co-led-by-ysios-capital-and-orbimed-to-advance-galectin-inhibitor-to-lat 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/rewind-therapeutics-appoints-leading-neuroscience-drug-developer-ian-j-reynolds-as-chief-executive-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/vaximm-announces-regional-development-and-commercialization-agreement-with-china-medical-system-holdings 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/macrophage-pharma-announces-appointment-of-leading-international-scientific-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/vesalius-biocapital-iii-partners-joins-forendo-pharma-investor-syndicate 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/apogen-biotechnologies-expands-series-a-financing-to-11-million-and-enhances-leadership-team 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-announces-84-million-65-million-series-b-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-s-tau-modifier-asn120290-receives-orphan-drug-designation-for-progressive-supranuclear-palsy-from-the-fda 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/mosa-meat-raises-7-5m-to-commercialise-cultured-meat 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/forendo-pharma-initiates-phase-i-study-for-potential-new-targeted-treatment-for-endometriosis 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-further-strengthens-its-scientific-advisory-board-with-the-addition-of-john-lambert-phd-former-cso-of-immunogen 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-completes-55-million-financing-to-advance-company-s-digital-medicine-platform-and-product-pipeline-aimed-at-treating-cogni 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/medisafe-demonstrates-double-digit-impact-on-medication-adherence-in-hypertension-patients 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/macrophage-pharma-appoints-dr-michael-moore-as-chairman 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-wins-life-science-innovation-award 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/forendo-pharma-receives-3-million-loan-from-business-finland-to-develop-novel-treatments-for-endometriosis 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/lundbeck-to-acquire-prexton-therapeutics-adding-foliglurax-in-clinical-phase-ii-to-its-pipeline-of-innovative-treatments-for-pat 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/david-colpman-joins-the-board-of-directors-of-forendo-pharma 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/m-ventures-invests-in-clearink-displays 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-exercises-option-to-in-license-potential-first-in-class-nuclease-development-programme 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-appoints-pierre-legault-as-chairman-of-its-board-of-directors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-appoints-distinguished-professor-and-nobel-prize-winner-professor-thomas-cech-as-scientific-advisor 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-extends-series-a-round-to-include-new-investor-taiho-ventures 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/rewind-therapeutics-secures-15-2-m-euro-to-develop-novel-remyelination-therapies 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/aveni-s-a-extends-copper-interconnects-to-5nm-and-below-for-beol-integration-using-innovative-electroplating-chemistry 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-announces-appointments-to-scientific-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-launches-toxsyn-a-new-platform-of-adc-payloads 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-achieves-primary-efficacy-endpoint-in-pediatric-adhd-pivotal-trial 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-commands-ip-space-of-glycan-conjugated-adcs-through-major-expansion-of-granted-patent-portfolio 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/ionctura-announces-appointment-of-leading-international-scientific-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/biolinq-completes-10m-series-a-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-announces-publication-in-nature-on-rna-epigenetics-by-founder-professor-tony-kouzarides 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/the-iqvia-institute-for-human-data-science-s-latest-report-names-medisafe-as-the-top-free-publicly-available-app-for-medication- 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-strengthens-board-with-appointment-of-professor-paul-workman-president-and-ceo-of-the-institute-of-cancer-res 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/two-global-leaders-in-technology-and-healthcare-join-list-of-venture-capitalists-investing-in-wiliot-to-scale-iot-with-battery-f 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/padlock-therapeutics-appoints-adelene-perkins-to-board-of-directors 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/taking-rna-epigenetics-by-storm 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/adc-therapeutics-triggers-second-target-specific-license-to-synaffix-adc-platform-under-existing-agreement 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/forendo-pharma-nominates-world-class-scientific-advisory-board-and-elects-professor-linda-giudice-as-the-chairperson 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-awarded-runner-up-postion-for-best-platform-adc-technology 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-wins-life-science-young-company-of-the-year-and-uk-private-finance-raise-at-the-biotech-and-money-annual-awards-20 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/vaximm-receives-orphan-designation-for-the-european-union-and-the-us-for-oral-t-cell-immunotherapy-vxm01-to-treat-glioma 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/m-ventures-participates-in-dna-script-successful-series-a-fundraising-of-11-m-to-advance-development-of-its-dna-synthesis-techno 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-appoints-dr-graeme-smith-as-chief-scientific-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/macrophage-pharma-limited-extends-series-a-round-to-include-new-investor-m-ventures 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/alcan-a-german-smart-antenna-start-up-raises-eur-7-5-million-to-manufacture-flat-panel-phased-array-antennas 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-expands-collaboration-with-evotec-on-storm-s-rna-epigenetics-platform 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/parkinson-s-disease-prexton-announces-initiation-of-phase-ii-clinical-testing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-announces-presentations-related-to-its-assisted-reproductive-technology-art-and-pre-term-labor-ptl-development-programs-a 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-announces-formation-of-world-leading-scientific-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-sa-announces-the-completion-of-a-phase-1-pk-pd-clinical-trial-evaluating-different-doses-of-obe2109-and-add-back-therapy 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/vaximm-announces-data-from-phase-i-trial-in-glioblastoma-with-oral-t-cell-immunotherapy-vxm01-to-be-presented-at-asco-2017-annua 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-secures-end-to-end-patent-protection-of-its-adc-technology-platform-as-its-hydraspace-patent-grants-in-the-united-state 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-sa-to-hold-first-quarter-2017-financial-results-and-business-update-call-on-thursday-may-18-2017 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/vaximm-announces-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer-to-evaluate-combination-of-vxm01-with-avelumab-in-gl 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/vaximm-to-present-preclinical-data-on-three-novel-oral-t-cell-immunotherapies-at-aacr-annual-meeting-2017 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/calypso-biotech-licenses-caly-001-best-in-class-anti-mmp-9-antibody-to-ea-pharma 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-sa-to-attend-needham-annual-healthcare-conference-in-nyc 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-starts-phase-3-clinical-program-for-nolasiban-in-art 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/medisafe-raises-14-5m-in-funding-to-support-rapid-growth-and-global-expansion 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-appoints-ceo-and-chairman 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/new-data-demonstrate-significant-expansion-of-therapeutic-index-vs-cysteine-engineered-adcs 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/prexton-therapeutics-series-b-financing-round-raises-29-million-31m-to-advance-its-novel-parkinson-s-therapeutic 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-sa-announces-pricing-of-initial-public-offering 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-expands-leadership-team-and-board-of-directors-with-industry-veterans 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-announces-completion-of-phase-1-first-in-women-study-of-obe022-for-the-treatment-of-preterm-labor 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artsavit-ltd-completes-6-3-million-series-a-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/key-synaffix-patent-covering-glycan-conjugated-adc-process-granted-in-the-united-states 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-appoints-j-michael-ryan-m-d-as-chief-medical-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-ltd-strengthened-management-team-with-the-appointment-of-dr-simon-boulton-as-vice-president-science-strategy 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-announces-results-of-the-implant-phase-2-trial-of-obe001-nolasiban-for-the-improvement-of-pregnancy-and-live-birth-rates- 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-enters-into-a-commercial-license-agreement-with-adc-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-announces-plans-to-conduct-initial-public-offering-in-the-united-states 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-randomizes-first-patient-in-phase-2b-edelweiss-study-of-obe2109-for-the-treatment-of-endometriosis 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/iomx-therapeutics-raises-eur-40-million-in-series-a-round 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/artios-pharma-company-launch-and-fundraising-of-33-2-million-to-focus-on-novel-dna-damage-response-ddr-cancer-therapies 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/parkinson-s-disease-prexton-therapeutics-completes-phase-1-clinical-trial 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/akili-adds-amgen-ventures-and-m-ventures-to-series-b-financing-increasing-round-to-42-4-million 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/synaffix-achieves-significantly-improved-therapeutic-index-compared-to-both-fda-approved-adcs-and-expands-its-scientific-advisor 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/storm-therapeutics-raises-12-million-series-a-funding-to-target-enzymes-that-modify-rna-to-generate-novel-cancer-therapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/cancer-metabolism-company-metabomed-completes-18-million-series-a-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/parkinson-s-disease-prexton-therapeutics-starts-phase-1-clinical-trial 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/f-star-enters-into-collaborative-discovery-development-agreement-with-abbvie-for-bispecific-antibodies-in-immuno-oncology 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/padlock-therapeutics-creates-west-coast-operations-appointing-scientific-co-founder-kerri-mowen-ph-d-as-director-of-biology-base 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/bird-rock-bio-announces-corporate-name-change-from-ruiyi-inc 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-closes-chf-60-usd-60-million-in-series-b-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/canbex-therapeutics-announces-start-of-phase-ii-trial-of-vsn16r-for-spasticity 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/padlock-therapeutics-an-unconventional-approach-to-autoimmunity 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/f-star-appoints-dr-neil-brewis-as-chief-scientific-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/padlock-therapeutics-named-by-fiercebiotech-as-a-2015-fierce15-biotech-company 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-raises-chf-30-million-in-a-series-a-financing-round-led-by-sofinnova-partners 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/rana-therapeutics-secures-55-million-in-oversubscribed-series-b-financing 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/padlock-therapeutics-accelerates-pipeline-development-through-agreement-with-gsk 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/raze-therapeutics-announces-addition-of-robert-copeland-phd-to-scientific-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/chinese-consortium-enters-into-agreement-to-acquire-ambrx 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/gilead-sciences-acquires-epitherapeutics 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/padlock-therapeutics-assembles-scientific-advisory-board-with-world-leaders-in-pad-enzyme-biology-and-autoimmune-disease 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/announcing-progyny-combining-best-in-class-clinical-solutions-with-consumer-expertise 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/alzheimer-s-drug-discovery-foundation-awarded-a-usd-325-000-grant-to-support-the-development-of-asceneuron-s-tau-modulators 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/in-new-nature-paper-raze-therapeutics-co-founder-david-sabatini-discovers-role-for-1c-metabolism-in-glioblastoma 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/padlock-therapeutics-initiates-collaborations-with-three-leading-research-partners-on-the-biology-of-pad-enzymes 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/raze-therapeutics-appoints-mark-manfredi-as-chief-scientific-officer 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/the-eeva-test-is-now-available-to-help-ivf-patients-in-the-united-states 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/auxogyn-and-fertility-authority-to-merge 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-the-road-to-tau 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/obseva-reports-positive-phase-1-results-for-the-first-orally-active-oxytocin-antagonist-obe001-to-treat-preterm-labour 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/canbex-therapeutics-enters-into-option-agreement-with-ipsen 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/prexton-therapeutics-raises-8-7-million-euros-10-million-dollars-in-a-series-a-round 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/asceneuron-appoints-leading-experts-to-scientific-advisory-board 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/evotec-and-padlock-therapeutics-announce-initial-success-and-extension-of-long-term-collaboration 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/news/raze-therapeutics-announces-addition-of-julian-adams-phd-george-q-daley-md-phd-and-karen-vousden-phd-to-scientific-advisory-boar 2024-03-12T07:54:39+00:00 0.64 https://www.m-ventures.com/team/therese-liechtenstein 2024-03-12T07:54:39+00:00 0.51 https://www.m-ventures.com/http:/www.akiliinteractive.com/programs-products/ 2024-03-12T07:54:39+00:00 0.51 https://www.m-ventures.com/http:/http://forendo.com 2024-03-12T07:54:39+00:00 0.51 https://www.m-ventures.com/http:/https://www.akiliinteractive.com/home/ 2024-03-12T07:54:39+00:00 0.51 https://www.m-ventures.com/http:/www.synaffix.com/ 2024-03-12T07:54:39+00:00 0.51 https://www.m-ventures.com/http:/www.utexas.edu%20/ 2024-03-12T07:54:39+00:00 0.51 https://www.m-ventures.com/http:/forendo.com/ 2024-03-12T07:54:39+00:00 0.51 https://www.m-ventures.com/http:/www.merckgroup.com/ 2024-03-12T07:54:39+00:00 0.51